دورية أكاديمية
أعرض في EDS

Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression.

التفاصيل البيبلوغرافية
العنوان: Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression.
المؤلفون: Wang P; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China., Wang M; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China., Hu Y; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China., Chen J; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China., Cao Y; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China., Liu C; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China., Wu Z; Department of Cardiac Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China., Shen J; Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong Pharmaceutical University, Guangzhou 510006, China., Lu J; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China., Liu P; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.; Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou 510006, China.; Guangdong Provincial Engineering Laboratory of Druggability and New Drugs Evaluation, Guangzhou 510006, China.
المصدر: Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2021 Mar; Vol. 11 (3), pp. 680-693. Date of Electronic Publication: 2020 Nov 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101600560 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2211-3835 (Print) Linking ISSN: 22113835 NLM ISO Abbreviation: Acta Pharm Sin B Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier, 2011-
مستخلص: As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time- and dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription factor TEA domain 1 (TEAD1) and plays an important role in cell proliferation and survival. However, the role of YAP1 in Dox-induced cardiomyopathy has not been reported. In this study, the expression of YAP1 was reduced in clinical human failing hearts with dilated cardiomyopathy and Dox-induced in vivo and in vitro cardiotoxic model. Ectopic expression of Yap1 significantly blocked Dox-induced cardiomyocytes apoptosis in TEAD1 dependent manner. Isorhapontigenin (Isor) is a new derivative of stilbene and responsible for a wide range of biological processes. Here, we found that Isor effectively relieved Dox-induced cardiomyocytes apoptosis in a dose-dependent manner in vitro . Administration with Isor (30 mg/kg/day, intraperitoneally, 3 weeks) significantly protected against Dox-induced cardiotoxicity in mice. Interestingly, Isor increased Dox-caused repression in YAP1 and the expression of its target genes in vivo and in vitro . Knockout or inhibition of Yap1 blocked the protective effects of Isor on Dox-induced cardiotoxicity. In conclusion, YAP1 may be a novel target for Dox-induced cardiotoxicity and Isor might be a new compound to fight against Dox-induced cardiotoxicity by increasing YAP1 expression.
(© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.)
References: Nat Rev Cardiol. 2018 Nov;15(11):672-684. (PMID: 30111784)
J Physiol Biochem. 2016 Sep;72(3):469-84. (PMID: 27193109)
BMC Cancer. 2018 Jul 3;18(1):711. (PMID: 29970036)
J Cell Physiol. 2018 Feb;233(2):1104-1119. (PMID: 28422286)
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2394-9. (PMID: 22308401)
Toxicology. 2015 Aug 6;334:1-11. (PMID: 25997894)
Cell Physiol Biochem. 2013;32(6):1808-17. (PMID: 24356001)
Front Pharmacol. 2018 Jul 11;9:753. (PMID: 30050440)
Inflammation. 2019 Dec;42(6):2278-2285. (PMID: 31512108)
Biomed Pharmacother. 2019 Jul;115:108956. (PMID: 31096145)
J Cell Biol. 2018 Oct 1;217(10):3464-3479. (PMID: 30037926)
Cardiovasc Toxicol. 2005;5(3):257-67. (PMID: 16244371)
Circ Res. 2015 Jan 2;116(1):35-45. (PMID: 25249570)
Int J Mol Sci. 2016 Jan 21;17(1):. (PMID: 26805820)
Theranostics. 2019 Jan 1;9(2):466-476. (PMID: 30809287)
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13839-44. (PMID: 23918388)
Dev Cell. 2018 Apr 23;45(2):153-169.e6. (PMID: 29689192)
Br J Pharmacol. 2019 Jul;176(14):2465-2481. (PMID: 30932177)
J Control Release. 2018 Jan 10;269:177-188. (PMID: 29146241)
Sci Signal. 2011 Oct 25;4(196):ra70. (PMID: 22028467)
Mol Ther Nucleic Acids. 2018 Sep 7;12:337-349. (PMID: 30195772)
Cardiovasc Res. 2020 Apr 1;116(5):970-982. (PMID: 31346605)
Indian Heart J. 2018 Dec;70 Suppl 3:S96-S100. (PMID: 30595329)
Cell Death Differ. 2019 Dec;26(12):2758-2773. (PMID: 31092884)
Clin Cardiol. 1998 Oct;21(10):777-9. (PMID: 9789703)
Circ Res. 2014 Jul 18;115(3):354-63. (PMID: 24833660)
Free Radic Biol Med. 2005 Jan 15;38(2):243-57. (PMID: 15607907)
Br J Cancer. 2007 Oct 22;97(8):1084-9. (PMID: 17940501)
Mol Cancer Res. 2013 Jul;11(7):748-58. (PMID: 23594797)
Nat Commun. 2017 Feb 27;8:14582. (PMID: 28239148)
Arch Toxicol. 2019 Feb;93(2):533-546. (PMID: 30377735)
Science. 2011 Apr 22;332(6028):458-61. (PMID: 21512031)
Genes Dev. 2019 Nov 1;33(21-22):1491-1505. (PMID: 31558567)
Carcinogenesis. 2018 Mar 8;39(3):482-492. (PMID: 29409027)
Int J Cardiol. 2016 Feb 15;205:99-110. (PMID: 26730840)
Nat Med. 2012 Nov;18(11):1639-42. (PMID: 23104132)
Food Chem. 2012 Dec 1;135(3):1353-9. (PMID: 22953865)
Nat Commun. 2014;5:3315. (PMID: 24525530)
Cardiovasc Res. 2020 May 1;116(6):1161-1174. (PMID: 31566215)
Autophagy. 2016 Aug 2;12(8):1229-39. (PMID: 27171279)
J Biol Chem. 2012 Apr 6;287(15):11730-9. (PMID: 22337891)
Cell Mol Life Sci. 2020 Jan;77(2):351-363. (PMID: 31222373)
BMC Cardiovasc Disord. 2012 Aug 06;12:63. (PMID: 22867422)
Oncol Lett. 2016 Apr;11(4):2941-2945. (PMID: 27073580)
Cell Mol Life Sci. 2015 Jan;72(2):285-306. (PMID: 25266986)
J Biol Chem. 2013 Feb 8;288(6):3977-88. (PMID: 23275380)
Nat Rev Mol Cell Biol. 2019 Apr;20(4):211-226. (PMID: 30546055)
Eur J Pharmacol. 2019 Nov 5;862:172627. (PMID: 31461638)
Br J Pharmacol. 2017 Jul;174(13):2043-2059. (PMID: 28369685)
Biomed Res Int. 2014;2014:282657. (PMID: 25050334)
Acta Pharm Sin B. 2019 Jul;9(4):782-793. (PMID: 31384538)
J Biochem. 2012 Sep;152(3):209-11. (PMID: 22761457)
Free Radic Res. 2009 Mar;43(3):195-205. (PMID: 19169920)
J Mol Cell Cardiol. 2019 Aug;133:125-137. (PMID: 31199952)
J Mol Cell Cardiol. 2012 Jun;52(6):1213-25. (PMID: 22465037)
J Mol Cell Cardiol. 2017 Mar;104:1-8. (PMID: 28108310)
PLoS Genet. 2019 Feb 21;15(2):e1007977. (PMID: 30789911)
J Mol Cell Cardiol. 2015 Feb;79:92-103. (PMID: 25446184)
Int J Biol Markers. 2017 Jul 24;32(3):e319-e324. (PMID: 28430338)
Acta Pharmacol Sin. 2014 Sep;35(9):1207-14. (PMID: 25087998)
Ageing Res Rev. 2018 Nov;47:168-175. (PMID: 30110651)
Circ Res. 2015 Oct 23;117(10):891-904. (PMID: 26333362)
فهرسة مساهمة: Keywords: AMPK, AMP-activated protein kinase; AP-1, anti-microbial protein; AREG, amphiregulin; AUC/Dose, dose-normalized plasma exposures; Amphiregulin; Ang II, angiotensin II; CO, cardiac output; CTGF, connective tissue growth factor; Cardiomyocytes apoptosis; Cardiotoxicity; Cmax/Dose, dose-normalized maximal plasma concentrations; Connective tissue growth factor; DAB, 3,3′-diaminobenzidine; DMEM, Dulbecco's modified Eagle's medium; Dob, dobutamine; Dox, doxorubicin; Doxorubicin; EMT, epithelial mesenchymal transformation; FOXO1, forkhead box class O1; FS, fractional shortening; HE, hematoxylin–eosin; ISO, isoproterenol; Isor, isorhapontigenin; Isorhapontigenin; LVAW;d, left ventricular end-diastolic anterior wall thickness; LVAW;s, left ventricular end-systolic anterior wall thickness; LVEF, left ventricular ejection fraction; LVID;d, left ventricular end-diastolic internal diameter; LVID;s, left ventricular end-systolic internal diameter; LVPW;d, left ventricular end-diastolic posterior wall thickness; LVPW;s, left ventricular end-systolic posterior wall thickness; MAPK, mitogen-activated protein kinase; MI, myocardial infarction; NF-κB, nuclear factor kappa-B; NRCMs, neonatal rat cardiomyocytes; P2Y12 receptor, ADP receptor; PGC-1α, peroxisome proliferator-activated receptor γ coactivator-1α; PMSF, phenylmethanesulfonyl fluoride; PVDF, polyvinylidene fluoride; ROS, reactive oxygen species; SD, Sprague–Dawley; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SESN2, sestrin2; TCF4, T-cell factor 4; TEAD, TEA domain transcription factor proteins; TEAD1; TUNEL, TdT-mediated dUTP nick end labeling; WGA, wheat germ agglutinin; YAP1; YAP1, Yes-associated protein 1; qRT-PCR, quantitative real-time polymerase chain reaction; sgRNAs, sequence guiding RNAs; Δψm, mitochondrial membrane potential
تواريخ الأحداث: Date Created: 20210329 Latest Revision: 20210330
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7982427
DOI: 10.1016/j.apsb.2020.10.017
PMID: 33777675
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-3835
DOI:10.1016/j.apsb.2020.10.017